rent, I just put a link there to trademark info MDXG filed for Epiburn. It was discussed/announced at the ABA Burn conference yesterday in Chicago. Maybe we will get some info Tuesday.
two different things. how bout. Formal aproval won't come for maybe 2 years and that is for the first use for planters F. What the company is looking for is a transition letter that would allow the company to market the micronized (in all uses) pending all BLAs which is something they are not doing now, they merely take orders for it as of now. It would be akin to an admission by the FDA that they messed up the entire process and almost like them saying "we want you to go the BLA route on the micronized but since the product has been used for years not only with no adverse events but also is a grey area whether this should really even require a BLA at all, we will allow you to market it.
Exact comment was " Resolution of the FDA issues with micronized product is nearly complete, which will allow the company to resume promotion of its injectable products, thus re-activating one of the company’s growth drivers."
correct but there were also comments on recent calls that they are nearing completion
I think the upside on both MDXG and ADK are fairly close actually. Think both will go close to 2X current price. But, you do get a dividend in the meantime on ADK
The two highest reward lowest risk stocks I know over the course of this year are MDXG and ADK. I don't
Expect either to make it to 2016 and see no downside for either.
great post by OWT. Rebecca is ugly and smelly though. And by smelly I don't mean our local poster known as Smelly but referring to Rebecca's stench.
And, think about this doc. if Bruce is right, once micronized sales efforts begin, it is trading more like 4X forward revenue, half of what it should be
REBECCA you ignorant #$%$, "Resolution of the FDA issues with micronized product is nearly complete, which will allow the company to resume promotion of its injectable products"
Also from Lake Street "Resolution of the FDA issues with micronized product is nearly complete, which will allow the company to resume promotion of its injectable products". This is the single most important item that could launch the stock higher. Lake Street indicated that being able to begin to market the micronized could add $75 million in upside to 2015 revenue. Imagine seeing estimates go from $185M to $260M in a day.
MiMedx shares defended at Canaccord
Canaccord defended MiMedx following its report of Q1 revenue that slightly missed consensus. The firm noted revenues came in above their estimates, but just shy of consensus, due to the poor weather as well as reimbursement changes that went into effect on January 1. Canaccord also cited the addition of new health plan coverage of roughly150M lives and said the stock remains one the firm's favorite medtech names. anaccord reiterated its Buy rating and $14 price target on MiMedx shares
Q1 is always soft numbnuts which you would know if you knew anything about the company. So you can't copare Q4 to Q1 and look at quarter over quarter. But, why should anyone be surprised that your timing stinks. Afyer all Cez/Candy has been wrong from the beginning.
108% increase along with a dramatic increase in insurance coverage obtained as noted in the second PR. Bodes well going forward